Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2020

View Archived Issues

A stinging defeat for infections

Researchers develop a new murine model of seizures with Chd8 haploinsufficiency

DUSP6 is implicated in vascular disease and may be a therapeutic target

Abpro completes dosing in phase I trial of ABP-300 for COVID-19

Optimization of selective antagonists of vasopressin V1A receptor derived from triazolobenzazepines

Hyaluronan is present in the alveolar spaces in lungs of patients with fatal COVID-19

SARS-CoV-2 RNA genome can be targeted using small-molecule binders and RIBOTAC degraders

Phase III study of masitinib in severe asthma uncontrolled by ICS meets primary endpoint

Oxeia initiates phase II study of OXE-103 for concussions

Storm Therapeutics patents METTL3 inhibitors

Centauri Therapeutics divulges new antibacterials

Array BioPharma presents new PTPN11 inhibitors

First patient enrolled in MERKLIN 2 trial of domatinostat plus avelumab in MCC

New CDK inhibitors presented by Aurigene Discovery Technologies

Sorrento Therapeutics patents CD38-targeting antibodies

Poseida and TScan collaborate to develop TCR-T cell therapies for treatment of COVID-19

Second part of daratumumab CASSIOPEIA study in multiple myeloma meets primary endpoint

First-in-human injection of [68]Ga-NT-20.3 found to be well-tolerated without AEs

Phase I data presented for RP-L201 in patients with LAD-I

Gene therapy approaches tackle multiple forms of blindness

FDA clears Cyclo to open global phase III trial of Trappsol Cyclo for NPC in U.S.

MAb 5D3-mertansine antibody-drug conjugate shows efficacy in prostate cancer mouse models

Ultimovacs reports 5-year OS data from phase I trial of UV-1 in NSCLC

Nanoform targets initiation of first-in-human trial of nanoformed piroxicam before year-end

Daiichi initiates phase I trial of DS-1055 in advanced or metastatic solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...